JP2023520047A5 - - Google Patents
Info
- Publication number
- JP2023520047A5 JP2023520047A5 JP2022559873A JP2022559873A JP2023520047A5 JP 2023520047 A5 JP2023520047 A5 JP 2023520047A5 JP 2022559873 A JP2022559873 A JP 2022559873A JP 2022559873 A JP2022559873 A JP 2022559873A JP 2023520047 A5 JP2023520047 A5 JP 2023520047A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- cationic lipid
- optionally substituted
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025244099A JP2026048786A (ja) | 2020-04-01 | 2025-12-10 | フェノール酸脂質系カチオン性脂質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003698P | 2020-04-01 | 2020-04-01 | |
| US63/003,698 | 2020-04-01 | ||
| PCT/US2021/025128 WO2021202694A1 (en) | 2020-04-01 | 2021-03-31 | Phenolic acid lipid based cationic lipids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025244099A Division JP2026048786A (ja) | 2020-04-01 | 2025-12-10 | フェノール酸脂質系カチオン性脂質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520047A JP2023520047A (ja) | 2023-05-15 |
| JP2023520047A5 true JP2023520047A5 (enExample) | 2024-04-11 |
| JP7791103B2 JP7791103B2 (ja) | 2025-12-23 |
Family
ID=75625666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559873A Active JP7791103B2 (ja) | 2020-04-01 | 2021-03-31 | フェノール酸脂質系カチオン性脂質 |
| JP2025244099A Pending JP2026048786A (ja) | 2020-04-01 | 2025-12-10 | フェノール酸脂質系カチオン性脂質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025244099A Pending JP2026048786A (ja) | 2020-04-01 | 2025-12-10 | フェノール酸脂質系カチオン性脂質 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4126813A1 (enExample) |
| JP (2) | JP7791103B2 (enExample) |
| CN (2) | CN115667207B (enExample) |
| WO (1) | WO2021202694A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250268994A1 (en) | 2021-03-25 | 2025-08-28 | Translate Bio, Inc. | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof |
| CA3215606A1 (en) * | 2021-04-19 | 2022-10-27 | Shrirang KARVE | Improved compositions for delivery of mrna |
| EP4763287A2 (en) | 2021-09-03 | 2026-06-24 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| TW202438514A (zh) | 2022-12-20 | 2024-10-01 | 法商賽諾菲公司 | 鼻病毒mrna疫苗 |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| US20250381150A1 (en) | 2024-03-08 | 2025-12-18 | Genzyme Corporation | Lipid nanoparticles |
| WO2026003373A1 (en) | 2024-06-28 | 2026-01-02 | Sanofi | Phenolic acid lipid based cationic lipids |
| WO2026008743A1 (en) | 2024-07-02 | 2026-01-08 | Sanofi Pasteur Inc. | Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| WO2026142951A1 (en) | 2024-12-23 | 2026-07-02 | Genzyme Corporation | Pharmaceutical system |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| WO1999052894A1 (en) * | 1998-04-09 | 1999-10-21 | Meiji Seika Kaisha, Ltd. | Nitrogen-containing heterocyclic compounds having antiplatelet aggregation effect and medicinal use thereof |
| WO2015184256A2 (en) * | 2014-05-30 | 2015-12-03 | Shire Human Genetic Therapies, Inc. | Biodegradable lipids for delivery of nucleic acids |
| DK3386484T3 (da) * | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| JP2019519601A (ja) | 2016-05-18 | 2019-07-11 | モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ． | 急性間欠性ポルフィリン症の治療のためのポルホビリノゲン脱アミノ酵素をコードするポリヌクレオチド |
| US20180153822A1 (en) | 2016-11-10 | 2018-06-07 | Translate Bio, Inc. | Process of Preparing mRNA-Loaded Lipid Nanoparticles |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| US12076439B2 (en) * | 2018-05-24 | 2024-09-03 | Translate Bio, Inc. | Thioester cationic lipids |
| EP3849617A1 (en) * | 2018-09-14 | 2021-07-21 | Translate Bio, Inc. | Composition and methods for treatment of methylmalonic acidemia |
| CN110526885A (zh) * | 2019-08-20 | 2019-12-03 | 上海英诺富成生物科技有限公司 | 麦考酚酸的前体药物及其制备方法 |
-
2021
- 2021-03-31 CN CN202180039080.XA patent/CN115667207B/zh active Active
- 2021-03-31 CN CN202511243318.7A patent/CN121318756A/zh active Pending
- 2021-03-31 JP JP2022559873A patent/JP7791103B2/ja active Active
- 2021-03-31 EP EP21720636.6A patent/EP4126813A1/en active Pending
- 2021-03-31 WO PCT/US2021/025128 patent/WO2021202694A1/en not_active Ceased
-
2025
- 2025-12-10 JP JP2025244099A patent/JP2026048786A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2201224C2 (ru) | Соединения, активные в новом сайте на рецептор-регулируемых кальциевых каналах и используемые для лечения неврологических расстройств и заболеваний | |
| ES2163295T3 (es) | Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. | |
| JP2004514663A5 (enExample) | ||
| RU2005107314A (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью | |
| RU2003120798A (ru) | Новые производные n-(фенилсульфонил) глицина и их применение в терапии | |
| JP2022522694A5 (enExample) | ||
| RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
| JP2002543202A5 (enExample) | ||
| JP2023531709A5 (enExample) | ||
| RU2007111758A (ru) | Аминопроизводные 7- амино-3-фенилдигидропиримидо [4,5-d] пиримидинонов, их получение и применение в качестве ингибиторов протеинкиназ | |
| CN102083773A (zh) | {f-19}标记的l-谷氨酸和l-谷氨酰胺衍生物(ⅲ)、其用途和制备方法 | |
| JP2023538524A5 (enExample) | ||
| JPH0920659A5 (enExample) | ||
| JP2024545787A5 (enExample) | ||
| EP1261349A1 (en) | Compounds with chelation affinity and selectivity for first transition series elements and their use | |
| JP2023531495A5 (enExample) | ||
| KR0130977B1 (ko) | 항종양제로서 폴리아민 유도체 | |
| JP2004523478A5 (enExample) | ||
| JP2012506908A5 (enExample) | ||
| RU2002118700A (ru) | Замещенные производные норборниламина, способ их получения, их применение в качестве медикаментов или диагностических средств, а также содержащие их медикаменты | |
| JP6017766B2 (ja) | 新規な金属サレン錯体化合物の抗がん剤 | |
| IL97902A (en) | Tetra-aza macrocycles processes for their preparation and their use in magnetic resonance imaging | |
| JP2004536079A5 (enExample) | ||
| CA2635093A1 (en) | Derivatives of sulindac, use thereof and preparation thereof | |
| JP2023541040A5 (enExample) |